In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Cipla Limited

Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities

A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.

Strategy Sales & Earnings

Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities

A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.

Commercial Sales & Earnings

Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Intellectual Property Policy & Regulation

Speed Bumps Ahead For IP Waiver, But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Medical Devices
  • Pharmaceuticals
  • Services
    • Consulting Services
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Cipla Gulf FZ LLC
    • Cipla Technologies LLC
    • InvaGen Pharmaceuticals Inc.
    • Mirren Pty, Ltd.
UsernamePublicRestriction

Register